Skip to main content

Advertisement

Table 1 Demographics, clinical characteristics, and CSF biomarker characteristics in DLB, AD, and controls

From: Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

  DLB (n = 72) AD (n = 38) Controls (n = 38)
Female (n, %) 7 (10%) 3 (8%) 5 (13%)
Age (mean ± SD) 68 ± 6 68 ± 6 67 ± 6
MMSE (median [IQR]) 23 [21–26]b 22 [18–25]b 29 [28–30]
APOEε4 carrier (n, %) 39 (57%)a 26 (72%)a 12 (32%)
CSF AD biomarkers Innotest (median [IQR])
 Aβ1-42 (pg/ml)* 790 [638–1040]b,d 620 [562–660]b 1123 [1022–1291]
 t-tau (pg/ml) 306 [228–368]b,d 611 [498–791]b 230 [187–271]
 p-tau (pg/ml) 47 [35–60]d 79 [65–99]b 44 [34–50]
 CSF tau/Aβ42 > 0.52 (n, %) 23 (33%)b,d 38 (100%)b 0 (0%)
CSF Aβ peptides MSD (mean ± SD)
 Aβ42 (pg/ml) 441 ± 185b,d 304 ± 71b 692 ± 205
 Aβ40 (pg/ml) 5432 ± 1340a 5897 ± 1066 6243 ± 1500
 Aβ38 (pg/ml) 2247 ± 638a,c 2524 ± 547 2676 ± 703
 Aβ42/Aβ40 ratio 0.08 ± 0.03b,d 0.05 ± 0.01b 0.11 ± 0.02
 Aβ42/Aβ38 ratio 0.20 ± 0.07b,d 0.12 ± 0.03b 0.26 ± 0.04
 Aβ38/Aβ40 ratio 0.41 ± 0.03a,c 0.43 ± 0.04 0.43 ± 0.02
  1. Data are presented as mean ± SD, median [interquartile range], or n (%). Differences between groups were assessed with ANOVA, χ2, and Kruskal-Wallis H tests where appropriate. For CSFAβ peptides, differences between diagnostic groups were assessed using ANOVA corrected for multiple comparisons using a false discovery rate (FDR) correction
  2. Abbreviations: Aβ42 amyloid β1-42 determined with MSD ELISA assay, Aβ40 amyloid β1-40 determined with MSD ELISA assay, Aβ38 amyloid β1-38 determined with MSD ELISA assay, AD Alzheimer’s disease, DLB dementia with Lewy bodies, MMSE mini-mental state examination, MSD Meso Scale Discovery
  3. ap < 0.05 compared to controls; bp < 0.001 compared to controls; cp < 0.05 compared to AD; dp < 0.001 compared to AD
  4. *Levels of Innotest Aβ1-42 were drift corrected [28]